Toronto Dominion Bank boosted its position in Illumina (NASDAQ:ILMN) by 25.9% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 79,172 shares of the life sciences company’s stock after acquiring an additional 16,281 shares during the period. Toronto Dominion Bank owned 0.05% of Illumina worth $18,714,000 as of its most recent SEC filing.
Other institutional investors have also recently made changes to their positions in the company. Lido Advisors LLC bought a new stake in shares of Illumina during the first quarter valued at about $397,000. Gamco Investors INC. ET AL bought a new stake in shares of Illumina during the first quarter valued at about $1,128,000. Gabelli Funds LLC increased its position in shares of Illumina by 260.5% during the first quarter. Gabelli Funds LLC now owns 41,100 shares of the life sciences company’s stock valued at $9,717,000 after buying an additional 29,700 shares during the period. Scout Investments Inc. increased its position in shares of Illumina by 77.0% during the first quarter. Scout Investments Inc. now owns 108,754 shares of the life sciences company’s stock valued at $25,712,000 after buying an additional 47,308 shares during the period. Finally, Federated Investors Inc. PA increased its position in shares of Illumina by 3,088.6% during the first quarter. Federated Investors Inc. PA now owns 492,287 shares of the life sciences company’s stock valued at $116,387,000 after buying an additional 476,848 shares during the period. Institutional investors and hedge funds own 90.75% of the company’s stock.
Several equities research analysts have recently weighed in on the company. Barclays upgraded Illumina from an “equal weight” rating to an “overweight” rating and set a $235.00 price target on the stock in a research report on Monday, May 7th. ValuEngine cut Illumina from a “buy” rating to a “hold” rating in a research report on Thursday, April 26th. Morgan Stanley upped their price target on Illumina from $170.00 to $180.00 and gave the company an “underweight” rating in a research report on Wednesday, April 25th. BTIG Research reiterated a “hold” rating on shares of Illumina in a research report on Wednesday, April 25th. Finally, Robert W. Baird upped their price target on Illumina from $261.00 to $271.00 and gave the company an “outperform” rating in a research report on Wednesday, April 25th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $251.14.
Shares of NASDAQ ILMN opened at $266.22 on Friday. Illumina has a 12 month low of $167.98 and a 12 month high of $273.93. The company has a quick ratio of 2.41, a current ratio of 2.71 and a debt-to-equity ratio of 0.23. The stock has a market cap of $39.13 billion, a PE ratio of 66.56, a price-to-earnings-growth ratio of 2.74 and a beta of 0.86.
Illumina (NASDAQ:ILMN) last issued its earnings results on Tuesday, April 24th. The life sciences company reported $1.45 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.02 by $0.43. The business had revenue of $782.00 million during the quarter, compared to analyst estimates of $744.30 million. Illumina had a return on equity of 24.93% and a net margin of 19.31%. Illumina’s revenue for the quarter was up 30.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.64 earnings per share. sell-side analysts anticipate that Illumina will post 4.86 EPS for the current year.
In other Illumina news, Director Robert S. Epstein sold 250 shares of the company’s stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $231.25, for a total value of $57,812.50. Following the completion of the sale, the director now owns 7,088 shares of the company’s stock, valued at $1,639,100. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Omead Ostadan sold 1,329 shares of the company’s stock in a transaction that occurred on Friday, March 2nd. The stock was sold at an average price of $222.66, for a total value of $295,915.14. Following the completion of the sale, the executive vice president now directly owns 29,392 shares of the company’s stock, valued at approximately $6,544,422.72. The disclosure for this sale can be found here. In the last ninety days, insiders sold 27,614 shares of company stock valued at $6,965,324. 0.54% of the stock is owned by insiders.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.